Achillion Pharmaceuticals is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from drug discovery to commercialization in its goal of providing better treatments for people with serious diseases. The Company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases.
TypePublic
HQNew Haven, US
Founded1998
Size (employees)81 (est)
Websiteachillion.com
Achillion Pharmaceuticals was founded in 1998 and is headquartered in New Haven, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Achillion Pharmaceuticals Office Locations

Achillion Pharmaceuticals has an office in New Haven
New Haven, US (HQ)
300 George St
Show all (1)
Report incorrect company information

Achillion Pharmaceuticals Financials and Metrics

Achillion Pharmaceuticals Revenue

Achillion Pharmaceuticals's revenue was reported to be $15 m in FY, 2016 which is a 77.3% decrease from the previous period.
USD

Net income (Q2, 2018)

(37.8m)

EBIT (Q2, 2018)

(40.4m)

Market capitalization (15-Oct-2018)

403.3m

Closing stock price (15-Oct-2018)

2.9

Cash (30-Jun-2018)

35.1m

EV

368.4m
Achillion Pharmaceuticals's current market capitalization is $403.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

66.1m15.0m

Revenue growth, %

(77%)

General and administrative expense

12.7m15.9m

R&D expense

46.7m53.5m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

711.0k711.0k33.8m

General and administrative expense

10.1m5.4m5.2m4.8m5.6m5.4m4.8m5.3m12.4m

R&D expense

19.8m13.3m14.2m16.7m15.5m18.3m15.6m14.8m26.1m

Operating expense total

29.9m18.7m19.3m21.5m21.1m23.6m20.5m21.8m40.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

33.5m73.7m81.7m77.3m

Accounts Receivable

223.2m

Inventories

2.5m1.9m2.7m3.5m

Current Assets

124.8m154.9m462.6m382.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

25.6m34.1m33.3m39.6m46.7m61.7m150.4m58.7m33.8m40.4m43.1m35.4m52.1m36.9m35.1m

Current Assets

141.9m142.6m133.6m128.7m255.6m249.5m465.3m443.0m429.1m411.8m383.4m355.2m327.0m309.5m291.9m

PP&E

2.7m2.6m

Total Assets

176.1m148.0m135.2m130.6m279.4m266.1m479.5m448.7m432.4m415.2m393.4m376.9m360.4m315.6m302.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(58.9m)(69.0m)(5.0m)(61.7m)

Depreciation and Amortization

399.0k489.0k694.0k955.0k

Inventories

(104.0k)575.0k(837.0k)(721.0k)

Accounts Payable

315.0k1.8m(2.3m)2.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(45.6m)(16.1m)(31.7m)(47.4m)(19.3m)(48.2m)(22.0m)(18.1m)(36.5m)(57.3m)(20.2m)(42.7m)(62.0m)(20.6m)(37.8m)

Depreciation and Amortization

296.0k111.0k232.0k353.0k160.0k321.0k505.0k192.0k432.0k690.0k295.0k565.0k842.0k289.0k571.0k

Accounts Payable

569.0k(950.0k)(2.6m)(2.0m)1.5m5.0m(1.5m)2.4m1.3m1.1m(2.7m)(3.9m)1.3m(2.8m)(3.8m)

Cash From Operating Activities

(39.7m)(13.4m)(27.2m)(39.3m)(17.3m)(34.2m)21.2m(16.2m)(33.1m)(48.5m)(5.8m)(22.7m)(24.1m)(37.3m)
USDY, 2018

EV/EBIT

-9.1 x

EV/CFO

-9.9 x

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

Achillion Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Achillion Pharmaceuticals News and Updates

Report incorrect company information

Achillion Pharmaceuticals Blogs

Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer

NEW HAVEN, Conn. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Anthony S. Gibney to the position of Executive Vice President and Chief Business Officer, effective immediately. Mr.

Achillion Reports Second Quarter 2018 Financial Results

- Global phase 2 clinical programs for ACH-4471 continue to expand in PNH and C3G - - Completed dosing phase 1 clinical study of ACH-5228 and initiated phase 1 study of ACH-5548 - - June 30, 2018 cash position $295.8 million - NEW HAVEN, Conn. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Achillion

Achillion Pharmaceuticals Company Life and Culture

Report incorrect company information